BG Medicine Outlines New Commercial Strategy

BG Medicine Outlines New Commercial Strategy

Company to Assume Greater Control of Commercial Execution

WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, today provided an update on its new
commercial strategy to speed the adoption of its cardiovascular diagnostic
tests – the BGM Galectin-3^® test and the CardioSCORE^TM test.

Under the plan announced today, BG Medicine has begun to build its own
dedicated sales organization and has taken steps to open its own CLIA lab in
order to play a more active role alongside its commercial partners in driving
sales and marketing efforts. In addition, the company highlighted its new
Galectin-3 promotion effort, and provided an update on the regulatory and
commercial path forward for CardioSCORE.

"We have taken a series of important steps over the past year to realign BG
Medicine into a more commercially-focused company, capable of playing a larger
role in facilitating the market adoption of our innovative cardiovascular
diagnostic tests," said Eric Bouvier, President and CEO of BG Medicine. "The
steps outlined today represent the culmination of our efforts to transform BG
Medicine. Taken together, these actions place us in a much stronger position
to control our own destiny and drive our own commercial success."

Highlights of the new commercial strategy include:

  *The launch of a major campaign to grow BGM Galectin-3 test sales in
    hospital settings. BG Medicine launched a new campaign earlier this month
    at the American Heart Association (AHA) Scientific Sessions 2012 focused
    on the urgent need to reduce rates of unplanned hospital readmissions. The
    CMS guidelines that went into effect on October 1, 2012 will result in new
    financial penalties expected to reach an aggregate of nearly $300 million
    in 2013 and nearly $1 billion by 2015, if improvements are not made.
    Because heart failure patients with elevated levels of galectin-3 are
    two-to-three times more likely than other heart failure patients to be
    readmitted to the hospital within 30 days of discharge, the company
    believes that identifying these high-risk patients through galectin-3
    testing is a potentially valuable and cost-effective tool in a hospital's
    strategy to reduce unplanned 30-day readmissions. The company expects this
    initiative will accelerate the sales ramp-up and the widespread adoption
    of galectin-3 testing.
  *The conversion of a medical liaison organization to a US-based sales
    organization. BG Medicine is transforming its current field force from an
    awareness- and education-focused organization into one with a sales
    mission and growth strategy. The field force will focus initially on
    promoting galectin-3 testing at a core set of hospitals with
    higher-than-average readmission rates, which are at risk of incurring
    significant financial penalties due to new rules affecting readmissions
    set by the Centers for Medicare & Medicaid Services (CMS).
  *The opening of a CLIA (Clinical Laboratory Improvement Amendments)
    certified clinical laboratory. BG Medicine expects to open the BG Medicine
    CLIA laboratory in the first half of 2013 in order to make galectin-3
    testing available to hospitals and other health care providers. The
    company expects this CLIA lab will further strengthen the company's own
    infrastructure to support sales made directly by BG Medicine.
  *Commercial strategy for CardioSCORE. BG Medicine is proceeding with the
    commercial offering of the CardioSCORE test in order to bring its benefits
    in the management of patients at risk of a cardiovascular event to
    physicians and patients as quickly as possible. To that end, BG Medicine
    is continuing its discussions with the FDA regarding 510(k) clearance for
    the CardioSCORE test kit.The company also expects to launch the
    CardioSCORE test initially in Europe through one or more partners,
    assuming receipt of a CE mark, which the company expects to receive in the
    first quarter of 2013.

In addition, the company announced a strategic reorganization in its research
and development department, away from its previous focus on early stage
discovery and toward a more commercially-oriented role in support of the BGM
Galectin-3 and CardioSCORE tests in the marketplace. As a result of this
reorganization, 11 positions in early discovery research have been eliminated,
enabling the company to dedicate a greater share of its R&D budget to
commercial support and market growth activities.

"The implementation of the aggressive new strategy announced today will be a
critical driver in our ongoing transformation into a full-scale commercial
organization," continued Mr. Bouvier. "This is an important time in the
evolution of BG Medicine and we look forward to sharing our progress in our
execution of this strategy with our shareholders."

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular diagnostics to
address significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company's first commercialized product, the BGM
Galectin-3^® test for use in patients with chronic heart failure, is available
in the United States and Europe.BG Medicine is also developing the
CardioSCORE^TM test, a blood test designed to aid in the assessment of an
individual's risk for near-term major cardiovascular events.For additional
information about BG Medicine, heart failure and galectin-3 testing, please
visit and

The BG Medicine Inc. logo is available at

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms.Forward-looking statements in this
news release address our beliefs that our new commercial strategy will place
us in a much stronger position to control our own destiny and drive our own
commercial success; our expectation that we will open our own CLIA lab in the
first half of 2013; our expectations that having our own CLIA lab will further
strengthen our ability to strengthen sales of our diagnostic tests; our belief
that identifying high-risk patients through galectin-3 testing is a
potentially valuable and cost-effective tool in a hospital's strategy to
reduce unplanned 30-day readmissions; our expectations that our hospital
readmissions initiative will accelerate the sales ramp-up and adoption of
galectin-3 testing; our intention to proceed with the commercial offering of
the CardioSCORE test; and our intention to launch the CardioSCORE test
initially in Europe through one or more partners.Forward-looking statements
are based on management's current expectations and involve inherent risks and
uncertainties which could cause actual results to differ materially from those
in the forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our recent filings with the Securities and Exchange
Commission, including our most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q.We urge you to consider those risks and uncertainties in
evaluating our forward-looking statements.We caution readers not to place
undue reliance upon any such forward-looking statements, which speak only as
of the date made.Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any updates or
revisions to any forward-looking statement contained herein (or elsewhere) to
reflect any change in our expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.